Figure 4. Survival of glioma patients with I-A, I-CF, and I-X genetic signatures.
Kaplan-Meier estimates of survival are shown for adult glioma patients, with the number of patients at risk at each time point for each group shown below the respective plot. Among all adult patients with grade II-IV gliomas (n=199), those with I-A tumors and with I-CF tumors survived significantly longer (median 51 and 96 months) than patients with I-X tumors (13 months; P <0.001 for both comparisons). Among grade III glioma patients with tumors of all histologies (n=69), there was a significant difference in survival between groups of patients with I-A or I-CF tumors and patients with I-X tumors (I-A and I-X, P = 0.002; I-CF and I-X, P <0.001). There was not a significant difference in survival when the same grade III glioma patients were stratified by the histopathological diagnosis of their tumors (P = 0.37). When all 199 grade II-IV gliomas were additionally stratified by IDH status, patients with I-A tumors and patients with I-CF tumors still survived significantly longer (median 51 and 96 months) than patients with IDH-mutated I-X tumors, and also longer than patients with IDH-WT I-X tumors (median 28 and 13 months, respectively; P <0.001 for all four comparisons). When grade III astrocytoma patients (n=39) were stratified by genetic signature and IDH status of their tumors, patients with I-A tumors survived longer (66 months) than grade III astrocytoma patients with either IDH-mutated I-X tumors (22 months, P = 0.005) and patients with IDH-WT I-X tumors (13 months, P = 0.002).